Small Stocks, Big Money™

Trinity Biotech (Nasdaq: TRIB) made a strategic investment in Novus Diagnostics to accelerate the development of its groundbreaking rapid sepsis testing platform. Novus is pioneering a 15-minute point-of-care diagnostic for bloodstream infections, aiming to significantly improve the detection and treatment of sepsis—a condition that affects 1.7 million people and causes 350,000 deaths annually in the U.S. Trinity's support will help fast-track regulatory approval and commercialization, addressing a $50 billion market for sepsis-related hospitalizations. The $2.5 million investment gives Trinity a 12.5% equity stake in Novus.

Nova Minerals (Nasdaq: NVA) reported impressive high-grade gold intercepts from its 2024 drilling program at the RPM starter pit, part of the Estelle Gold Project in Alaska. Highlights include 29m @ 7.1 g/t Au from surface, with exceptional grades such as 22m @ 9.4 g/t Au and 2m @ 52.7 g/t Au. These results extend the high-grade core to surface and will be incorporated into an upcoming resource update. With over 20 significant intercepts, Nova is advancing its low-cost, high-margin RPM starter mine, aiming to fund the larger Estelle Project—one of the largest undeveloped gold assets globally.

Soligenix (Nasdaq: SNGX) has received a patent from the Hong Kong Patent Office for its proprietary process of producing synthetic hypericin, the active ingredient in its flagship treatments: HyBryte™ for cutaneous T-cell lymphoma (CTCL) and SGX302 for psoriasis. This patent, part of a broader portfolio set to expire in 2036, bolsters Soligenix's intellectual property as it prepares to launch a confirmatory Phase 3 trial for HyBryte™ later this year. The company's photodynamic therapies aim to provide safe, effective treatment options without the risks of conventional therapies.

BullFrog AI (NASDAQ: BFRG) announced that its VP of Artificial Intelligence, Dr. Enrique García-Rivera, will present at Google’s inaugural Cancer AI Symposium on October 30, 2024. His presentation will highlight BullFrog AI's innovative use of AI in drug development, focusing on the bfLEAP™ platform, which integrates multimodal biological data to accelerate cancer research and drug discovery. Dr. García-Rivera will also introduce "AlgoLLM," a novel AI system for gene prioritization that uses large language models to enhance target identification. These advancements showcase BullFrog AI’s leadership in leveraging AI for drug discovery and therapeutic innovation.